Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Prothena

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Prothena to Present Data from Two of its Alzheimer’s Disease Programs

Details:

PRX012 is a next-generation, high-potency monoclonal antibody designed to deliver best-in-class efficacy, safety and patient experience for the treatment of AD. PRX012 binds to the N-terminus of Aβ, a key component of the plaques associated with AD.

Lead Product(s): PRX012

Therapeutic Area: Neurology Product Name: PRX012

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY